Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab

Davide Allegrini,1 Raffaele Raimondi,2 Giovanni Montesano,3 Alfredo Borgia,2 Tania Sorrentino,2 Panagiotis Tsoutsanis,2 Mario R Romano1,2 1Eye Center, Humanitas, Bergamo, Italy; 2Department of Biomedical Sciences, Humanitas University, Milano, Italy; 3University of London - Optometry and Visual Scie...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Allegrini D, Raimondi R, Montesano G, Borgia A, Sorrentino T, Tsoutsanis P, Romano MR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	ivt interruption covid-19 intravitreal injection bevacizumab Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/858c4ff36d404093b285de3b8f33c482
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:858c4ff36d404093b285de3b8f33c482
record_format	dspace
spelling	oai:doaj.org-article:858c4ff36d404093b285de3b8f33c4822021-12-02T17:13:24ZShort-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab1177-5483https://doaj.org/article/858c4ff36d404093b285de3b8f33c4822021-10-01T00:00:00Zhttps://www.dovepress.com/short-term-outcomes-after-covid-19-related-treatment-interruption-amon-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Davide Allegrini,1 Raffaele Raimondi,2 Giovanni Montesano,3 Alfredo Borgia,2 Tania Sorrentino,2 Panagiotis Tsoutsanis,2 Mario R Romano1,2 1Eye Center, Humanitas, Bergamo, Italy; 2Department of Biomedical Sciences, Humanitas University, Milano, Italy; 3University of London - Optometry and Visual Sciences, London, UKCorrespondence: Raffaele RaimondiDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milano, ItalyTel +39 02 8224 7100Email raffor9@gmail.comPurpose: To assess outcomes and recovery strategy of patients undergoing intravitreal injections for exudative age-related macular degeneration who experienced COVID-19 related interruption in treatment during complete lockdown.Methods: This was a retrospective, observational case study. We used a mixed effect model with random intercepts to evaluate best corrected visual acuity (BCVA) accounting for measured central macular thickness (CMT) and individual variability of each eye. Furthermore, we analysed measures of the pigmented epithelium detachment as well as presence of subretinal fluid and intraretinal cysts.Results: We included 39 patients and we found a significant reduction in the BCVA between the pre- and post-lockdown controlling for CMT. There was no significant difference in pigmented epithelium detachment and in presence of subretinal fluid and intraretinal cysts.Conclusion: We detected a significant loss in visual function. The magnitude of the average loss was, however, limited suggesting good efficacy of the recovery strategy.Keywords: IVT interruption, covid-19, intravitreal injection, bevacizumabAllegrini DRaimondi RMontesano GBorgia ASorrentino TTsoutsanis PRomano MRDove Medical Pressarticleivt interruptioncovid-19intravitreal injectionbevacizumabOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 4073-4079 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ivt interruption covid-19 intravitreal injection bevacizumab Ophthalmology RE1-994
spellingShingle	ivt interruption covid-19 intravitreal injection bevacizumab Ophthalmology RE1-994 Allegrini D Raimondi R Montesano G Borgia A Sorrentino T Tsoutsanis P Romano MR Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
description	Davide Allegrini,1 Raffaele Raimondi,2 Giovanni Montesano,3 Alfredo Borgia,2 Tania Sorrentino,2 Panagiotis Tsoutsanis,2 Mario R Romano1,2 1Eye Center, Humanitas, Bergamo, Italy; 2Department of Biomedical Sciences, Humanitas University, Milano, Italy; 3University of London - Optometry and Visual Sciences, London, UKCorrespondence: Raffaele RaimondiDepartment of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, Milano, ItalyTel +39 02 8224 7100Email raffor9@gmail.comPurpose: To assess outcomes and recovery strategy of patients undergoing intravitreal injections for exudative age-related macular degeneration who experienced COVID-19 related interruption in treatment during complete lockdown.Methods: This was a retrospective, observational case study. We used a mixed effect model with random intercepts to evaluate best corrected visual acuity (BCVA) accounting for measured central macular thickness (CMT) and individual variability of each eye. Furthermore, we analysed measures of the pigmented epithelium detachment as well as presence of subretinal fluid and intraretinal cysts.Results: We included 39 patients and we found a significant reduction in the BCVA between the pre- and post-lockdown controlling for CMT. There was no significant difference in pigmented epithelium detachment and in presence of subretinal fluid and intraretinal cysts.Conclusion: We detected a significant loss in visual function. The magnitude of the average loss was, however, limited suggesting good efficacy of the recovery strategy.Keywords: IVT interruption, covid-19, intravitreal injection, bevacizumab
format	article
author	Allegrini D Raimondi R Montesano G Borgia A Sorrentino T Tsoutsanis P Romano MR
author_facet	Allegrini D Raimondi R Montesano G Borgia A Sorrentino T Tsoutsanis P Romano MR
author_sort	Allegrini D
title	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
title_short	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
title_full	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
title_fullStr	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
title_full_unstemmed	Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
title_sort	short-term outcomes after covid-19-related treatment interruption among patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/858c4ff36d404093b285de3b8f33c482
work_keys_str_mv	AT allegrinid shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT raimondir shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT montesanog shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT borgiaa shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT sorrentinot shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT tsoutsanisp shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab AT romanomr shorttermoutcomesaftercovid19relatedtreatmentinterruptionamongpatientswithneovascularagerelatedmaculardegenerationreceivingintravitrealbevacizumab
_version_	1718381329069899776

Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab

Ejemplares similares